Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization.
about
Protein aggregation and its impact on product qualitySimultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperaturesStructure-based prediction of asparagine and aspartate degradation sites in antibody variable regionsHuman IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationGlycoproteome study in myocardial lesions serum by integrated mass spectrometry approach: preliminary insights.Biophysical chemistry of the ageing eye lens.Top-down study of β2-microglobulin deamidationSilk-based stabilization of biomacromolecules.Quantification of isotopically overlapping deamidated and 18o-labeled peptides using isotopic envelope mixture modelingBrain proteomics supports the role of glutamate metabolism and suggests other metabolic alterations in protein l-isoaspartyl methyltransferase (PIMT)-knockout miceThe role of thiols and disulfides on protein stability.State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation.Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy.Biopharmaceutical formulations for pre-filled delivery devices.Tailoring recombinant protein quality by rational media design.Protein asparagine deamidation prediction based on structures with machine learning methodsAssessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes.Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.Assessing analytical methods to monitor isoAsp formation in monoclonal antibodies.Characterization of recombinant human IL-15 deamidation and its practical elimination through substitution of asparagine 77.Glycolic acid-catalyzed deamidation of asparagine residues in degrading PLGA matrices: a computational study.Effects of carboxypeptidase B treatment and elevated temperature on recombinant monoclonal antibody charge variants in cation-exchange chromatography analysis.Molecular polygamy: The promiscuity of l-phenylalanyl-tRNA-synthetase triggers misincorporation of meta- and ortho-tyrosine in monoclonal antibodies expressed by Chinese hamster ovary cells.Detection and quantitation of succinimide in intact protein via hydrazine trapping and chemical derivatization.Acetic acid can catalyze succinimide formation from aspartic acid residues by a concerted bond reorganization mechanism: a computational study.Evaluation of the physical stability of the EC5 domain of E-cadherin: effects of pH, temperature, ionic strength, and disulfide bonds.Analysis of isoaspartic Acid by selective proteolysis with Asp-N and electron transfer dissociation mass spectrometry.Chemical and functional aspects of posttranslational modification of proteinsConjugation site heterogeneity causes variable electrostatic properties in Fc conjugates.In-Source Decay Characterization of Isoaspartate and β-Peptides.Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture ComponentsRacemized and Isomerized Proteins in Aging Rat Teeth and Eye Lens.Mapping site-specific changes that affect stability of the N-terminal domain of calmodulin.Development and scale-up of a commercial fed batch refolding process for an anti-CD22 two chain immunotoxin.Mass spectrometric distinction of in-source and in-solution pyroglutamate and succinimide in proteins: a case study on rhG-CSF.Sequence and Solution Effects on the Prevalence of d-Isomers Produced by Deamidation.Air sparging for prevention of antibody disulfide bond reduction in harvested CHO cell culture fluid.Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody.Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation.
P2860
Q27010661-3558FA18-248C-4CB7-A4B6-D07CC1F8FC4EQ28478926-7E078386-8627-45D3-82F1-0CDDB80FB4EDQ28539968-34227040-F2D8-45EF-B3DC-5AFCC3B282B3Q30360964-6B605DA2-668C-41E6-8299-34C4BDA72027Q33523250-D3D64222-E84A-43C7-B8EA-30FF479E43FDQ33639756-F979EC0A-6488-4260-B20C-B8576B823165Q34219743-73FFC184-367A-47A4-9A4C-0FFEF5AAC8FAQ36307700-0F68F6F7-1287-46F5-857E-47BEE43304F0Q37219931-570F2288-0D46-423B-A116-75AE85F90729Q37282869-F755E880-08C2-452E-8941-AF2D0F641C74Q37524089-C600530E-CC4D-4758-87CA-70C03D12F296Q38013999-630F31B7-6483-4B0E-ADCB-B8C833E3B579Q38020929-0C17583D-B481-4EBF-A55C-34F25FEB9C0EQ38047231-BD709FF4-87C1-4AEF-96EB-C313CD002F4CQ38090687-820A1160-9CE7-42CB-B096-27B011C3C1EBQ38416739-B0513227-19C0-4DBA-BED1-1A9021FD4C59Q38667917-79BFAB0B-97B2-476F-9224-EFD7846D6C1AQ38717942-7DC4EF47-CC87-487F-A618-6BC66A54A72AQ38910806-364E2E6C-1B24-4904-98DA-198F3CD075E6Q39252529-5854C700-8EF4-4686-B905-17F363A1679FQ39456212-834A28FF-54DB-4C3A-80CA-FAFF14A5F589Q40455725-E28CB04C-DC7E-4054-AC06-14A923FAE1E9Q40622943-0D224B5D-BC2C-4411-8388-5EEC141646D6Q41643081-C3416196-0355-4A65-9ED8-3EC909F4C404Q41833694-BE6AFBAA-FA34-4367-8BE5-C5D502E92AC5Q41856113-AEF97A17-75C8-4038-B3E8-72D93BB65A47Q41876888-EED316E7-2123-4B14-A361-A36C718150FFQ41970463-F0E200B7-94C1-4E94-9CE1-9A233F6961C9Q42153052-24791660-5774-4537-8EF8-CD50E147776BQ42174344-FDE53842-C326-412D-ABB9-112ABA656FDCQ42225476-33D80ACA-95CA-4FA0-AB3D-0EF2DC09FF66Q42363063-46E936D4-DB38-4E1F-BD05-3A7005964DB9Q42384168-62FFEB8B-C344-40F8-B5F1-598B5627B78EQ42551367-D4EEC914-B71E-4F42-BEA5-289AAC16A509Q43090431-EF256B47-F7B3-4177-8E3C-142F2D3541AFQ44517032-17D85117-F688-4E44-BAD3-7CAA4D0C1626Q45969140-9F26F1D8-40CE-490A-8987-FE1E1C104592Q46066148-AE4A4D4B-E790-4D04-BB27-76C9CC733E20Q46072087-7B83310E-5A53-42EE-A265-546D7136DEF8Q46114334-8DCD3224-A82A-4893-8019-87B55FAD11FC
P2860
Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Formulation considerations for ...... n and aspartate isomerization.
@ast
Formulation considerations for ...... n and aspartate isomerization.
@en
type
label
Formulation considerations for ...... n and aspartate isomerization.
@ast
Formulation considerations for ...... n and aspartate isomerization.
@en
prefLabel
Formulation considerations for ...... n and aspartate isomerization.
@ast
Formulation considerations for ...... n and aspartate isomerization.
@en
P356
P1476
Formulation considerations for ...... n and aspartate isomerization.
@en
P2093
Aditya A Wakankar
Ronald T Borchardt
P304
P356
10.1002/JPS.20740
P407
P577
2006-11-01T00:00:00Z